Gene mutations as emerging biomarkers and therapeutic targets for relapsed acute myeloid leukemia

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

It is believed that there are key differences in the genomic profile between adult and childhood acute myeloid leukemia (AML). Relapse is the significant contributor of mortality in patients with AML and remains as the leading cause of cancer death among children, posing great challenges in the treatment of AML. The knowledge about the genomic lesions in childhood AML is still premature as most genomic events defined in children were derived from adult cohorts. However, the emerging technologies of next generation sequencing have narrowed the gap of knowledge in the biology of AML by the detection of gene mutations for each sub-type which have led to the improvement in terms of prognostication as well as the use of targeted therapies. In this review, we describe the recent understanding of the genomic landscape including the prevalence of mutation, prognostic impact, and targeted therapies that will provide an insight into the pathogenesis of AML relapse in both adult and childhood cases.

Original languageEnglish
Article number897
JournalFrontiers in Pharmacology
Volume8
Issue numberDEC
DOIs
Publication statusPublished - 7 Dec 2017

Fingerprint

Acute Myeloid Leukemia
Biomarkers
Mutation
Genes
Therapeutics
Recurrence
Cause of Death
Technology
Mortality
Neoplasms

Keywords

  • Acute myeloid leukemia
  • Adult
  • Biomarker
  • Childhood
  • Mutation
  • Relapse

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{4a164cb0dcff4345ae1f1d9e20620cce,
title = "Gene mutations as emerging biomarkers and therapeutic targets for relapsed acute myeloid leukemia",
abstract = "It is believed that there are key differences in the genomic profile between adult and childhood acute myeloid leukemia (AML). Relapse is the significant contributor of mortality in patients with AML and remains as the leading cause of cancer death among children, posing great challenges in the treatment of AML. The knowledge about the genomic lesions in childhood AML is still premature as most genomic events defined in children were derived from adult cohorts. However, the emerging technologies of next generation sequencing have narrowed the gap of knowledge in the biology of AML by the detection of gene mutations for each sub-type which have led to the improvement in terms of prognostication as well as the use of targeted therapies. In this review, we describe the recent understanding of the genomic landscape including the prevalence of mutation, prognostic impact, and targeted therapies that will provide an insight into the pathogenesis of AML relapse in both adult and childhood cases.",
keywords = "Acute myeloid leukemia, Adult, Biomarker, Childhood, Mutation, Relapse",
author = "Habsah Aziz and {Yock Ping}, Chow and Hamidah Alias and {Ab Mutalib}, {Nurul Syakima} and {A. Jamal}, {A. Rahman}",
year = "2017",
month = "12",
day = "7",
doi = "10.3389/fphar.2017.00897",
language = "English",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "DEC",

}

TY - JOUR

T1 - Gene mutations as emerging biomarkers and therapeutic targets for relapsed acute myeloid leukemia

AU - Aziz, Habsah

AU - Yock Ping, Chow

AU - Alias, Hamidah

AU - Ab Mutalib, Nurul Syakima

AU - A. Jamal, A. Rahman

PY - 2017/12/7

Y1 - 2017/12/7

N2 - It is believed that there are key differences in the genomic profile between adult and childhood acute myeloid leukemia (AML). Relapse is the significant contributor of mortality in patients with AML and remains as the leading cause of cancer death among children, posing great challenges in the treatment of AML. The knowledge about the genomic lesions in childhood AML is still premature as most genomic events defined in children were derived from adult cohorts. However, the emerging technologies of next generation sequencing have narrowed the gap of knowledge in the biology of AML by the detection of gene mutations for each sub-type which have led to the improvement in terms of prognostication as well as the use of targeted therapies. In this review, we describe the recent understanding of the genomic landscape including the prevalence of mutation, prognostic impact, and targeted therapies that will provide an insight into the pathogenesis of AML relapse in both adult and childhood cases.

AB - It is believed that there are key differences in the genomic profile between adult and childhood acute myeloid leukemia (AML). Relapse is the significant contributor of mortality in patients with AML and remains as the leading cause of cancer death among children, posing great challenges in the treatment of AML. The knowledge about the genomic lesions in childhood AML is still premature as most genomic events defined in children were derived from adult cohorts. However, the emerging technologies of next generation sequencing have narrowed the gap of knowledge in the biology of AML by the detection of gene mutations for each sub-type which have led to the improvement in terms of prognostication as well as the use of targeted therapies. In this review, we describe the recent understanding of the genomic landscape including the prevalence of mutation, prognostic impact, and targeted therapies that will provide an insight into the pathogenesis of AML relapse in both adult and childhood cases.

KW - Acute myeloid leukemia

KW - Adult

KW - Biomarker

KW - Childhood

KW - Mutation

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=85037740042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037740042&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00897

DO - 10.3389/fphar.2017.00897

M3 - Review article

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - DEC

M1 - 897

ER -